Baird Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Axsome Therapeutics (AXSM) PT Raised to $124 at Cantor Fitzgerald
December 31, 2024 6:37 AM ESTCantor Fitzgerald analyst Charles C. Duncan raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $124.00 (from $121.00) while maintaining a Overweight rating.
The analyst comments "AXSM announced topline results from the P3 ACCORD-2 and ADVANCE-2 trials of AXS-05 (approved as AUVELITY in MDD) in Alz Dis agitation (ADA). We acknowledge todays results may be considered mixed, as ADVANCE-2 did not reach stat. sig. (AXSM trading -8% vs. -1% with the XBI). However, we believe that the clear ACCORD-2 data, combined with previously PR'd ADVANCE-1 data... More
Axsome Therapeutics (AXSM) PT Lowered to $122 at Mizuho
December 31, 2024 6:09 AM ESTMizuho analyst Graig Suvannavejh lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $122.00 (from $124.00) while maintaining a Outperform rating.
The analyst comments "Yesterday, AXSM announced highly anticipated P3 data for lead asset AXS-05 in Alzheimer's disease agitation/ADA, a significant, potential... More
